Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Santen Pharmaceutical Co ( (JP:4536) ) is now available.
Santen Pharmaceutical reported its consolidated financial results for the nine months ending December 31, 2024, showing slight revenue stability but a decrease in core operating and net profits. Despite this, the company forecasts a significant improvement in operating and net profits for the year ending March 31, 2025, indicating strategic adjustments, including share repurchases and cancellations, to enhance shareholder value.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily engaged in the pharmaceutical industry. They specialize in eye care products, focusing on developing and distributing medications for various ophthalmic conditions.
YTD Price Performance: -1.96%
Average Trading Volume: 1,359
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.47B
For detailed information about 4536 stock, go to TipRanks’ Stock Analysis page.